Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis
Lina Sahnoon, Rola Abujabal, Tasneem M Alanta, Bushra Mdkhana, Ronald Olivenstein, Ellen Puré, Bassam Mahboub, Yves Laumonnier, Rifat Hamoudi, Khuloud Bajbouj, Qutayba Hamid · 2026
Read Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis by Lina Sahnoon, Rola Abujabal, Tasneem M Alanta, Bushra Mdkhana, Ronald Olivenstein, Ellen Puré, Bassam Mahboub, Yves Laumonnier, Rifat Hamoudi, Khuloud Bajbouj, Qutayba Hamid (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13458785.txt.
Description
Lina Sahnoon and colleagues show how two immune signals jointly scar asthma airways, and how dupilumab blocks them, in a 2026 study. Airway scarring marks severe asthma, yet the combined role of IL-4 and IL-13 on human lung scar cells was unclear. Scar cells from asthma patients carried more type II receptor than normal scar cells, priming them for switch-on, and were dosed with both signals alone and together.
Combined dosing raised STAT6 signals far more than either alone. It strongly increased collagen types I and III, a sticky protein and matrix tuners MMP-9 and TIMP-1 and TIMP-2, while IL-4 alone drove growth most. The receptor-blocking drug dupilumab wiped out this scarring response. The work gives a direct route for aiming at the IL-4 receptor pathway to slow airway rebuild in severe type 2-high asthma.
Catalog record
| CREATOR | Lina Sahnoon, Rola Abujabal, Tasneem M Alanta, Bushra Mdkhana, Ronald Olivenstein, Ellen Puré, Bassam Mahboub, Yves Laumonnier, Rifat Hamoudi, Khuloud Bajbouj, Qutayba Hamid |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |